Canada Life’s Arbutus Biopharma ABUS Stock Holding History

Canada Life’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-39,900	Closed	-$473K	–	2438
2015 Q2	$473K	Hold	39,900	–	–	﹤0.01%	1019
2015 Q1	$695K	Buy	39,900 +23,400	+142%	+$479K	﹤0.01%	941
2014 Q4	$253K	Buy	+16,500	New	+$285K	﹤0.01%	1192

Other funds holding ABUS

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Canada Life's ABUS Position: Q3 2015 in Review

Canada Life sold out of Arbutus Biopharma (ABUS) in Q3 2015, closing a stake of 39,900 shares — an estimated $473K sold.

Canada Life first reported a position in ABUS in Q4 2014 and held it in 3 quarters. The position peaked at $695K in Q1 2015. 55 funds tracked by Wall St. Rank hold ABUS as of Q3 2015.

Canada Life reported no remaining Arbutus Biopharma position as of Q3 2015 after selling out during the quarter.
Canada Life sold 39,900 Arbutus Biopharma shares in Q3 2015, an estimated $473K.
Canada Life first reported a position in Arbutus Biopharma in Q4 2014 and held it in 3 quarters.
Canada Life's Arbutus Biopharma position peaked at $695K in Q1 2015.
55 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2015.

Based on Canada Life's 13F filing for Q3 2015, filed 10 Nov 2015.